Rebecka Ventin-Holmberg1, Anja Eberl2, Schahzad Saqib3, Katri Korpela3, Seppo Virtanen4, Taina Sipponen2, Anne Salonen3, Päivi Saavalainen1, Eija Nissilä1. 1. Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. 2. Department of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 3. Human Microbiome Research Program, University of Helsinki, Helsinki, Finland. 4. Obstetrics and Gynaecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND AND AIMS: Inflammatory bowel diseases [IBDs], Crohn's disease [CD] and ulcerative colitis [UC], are globally increasing chronic gastro-intestinal inflammatory disorders associated with altered gut microbiota. Infliximab [IFX], a tumour necrosis factor [TNF]-alpha blocker, is used to treat IBD patients successfully, though one-third of the patients do not respond to therapy. No reliable biomarkers are available for prediction of IFX response. Our aims were to investigate the faecal bacterial and fungal communities during IFX therapy and find predictors for IFX treatment response in IBD patients. METHODS: A total of 72 IBD patients [25 CD and 47 UC] started IFX therapy and were followed for 1 year or until IFX treatment was discontinued. An amplicon sequencing approach, targeting the bacterial 16S rRNA gene and fungal ITS 1 region separately, was used to determine the microbiota profiles in faecal samples collected before IFX therapy and 2, 6, and 12 weeks and 1 year after initiation of therapy. The response to IFX was evaluated by colonoscopy and clinically at 12 weeks after initiation. RESULTS: Both faecal bacterial and fungal profiles differed significantly between response groups before start of IFX treatment. Non-responders had lower abundances of short chain fatty acid producers, particularly of the class Clostridia, and higher abundances of pro-inflammatory bacteria and fungi, such as the genus Candida, compared with responders. This was further indicated by bacterial taxa predicting the response in both CD and UC patients [area under the curve >0.8]. CONCLUSIONS: Faecal bacterial and fungal microbiota composition could provide a predictive tool to estimate IFX response in IBD patients.
BACKGROUND AND AIMS: Inflammatory bowel diseases [IBDs], Crohn's disease [CD] and ulcerative colitis [UC], are globally increasing chronic gastro-intestinal inflammatory disorders associated with altered gut microbiota. Infliximab [IFX], a tumour necrosis factor [TNF]-alpha blocker, is used to treat IBD patients successfully, though one-third of the patients do not respond to therapy. No reliable biomarkers are available for prediction of IFX response. Our aims were to investigate the faecal bacterial and fungal communities during IFX therapy and find predictors for IFX treatment response in IBD patients. METHODS: A total of 72 IBD patients [25 CD and 47 UC] started IFX therapy and were followed for 1 year or until IFX treatment was discontinued. An amplicon sequencing approach, targeting the bacterial 16S rRNA gene and fungal ITS 1 region separately, was used to determine the microbiota profiles in faecal samples collected before IFX therapy and 2, 6, and 12 weeks and 1 year after initiation of therapy. The response to IFX was evaluated by colonoscopy and clinically at 12 weeks after initiation. RESULTS: Both faecal bacterial and fungal profiles differed significantly between response groups before start of IFX treatment. Non-responders had lower abundances of short chain fatty acid producers, particularly of the class Clostridia, and higher abundances of pro-inflammatory bacteria and fungi, such as the genus Candida, compared with responders. This was further indicated by bacterial taxa predicting the response in both CD and UC patients [area under the curve >0.8]. CONCLUSIONS: Faecal bacterial and fungal microbiota composition could provide a predictive tool to estimate IFX response in IBD patients.
Authors: Dagmar Schierova; Radka Roubalova; Martin Kolar; Zuzana Stehlikova; Filip Rob; Zuzana Jackova; Stepan Coufal; Tomas Thon; Martin Mihula; Martin Modrak; Miloslav Kverka; Lukas Bajer; Klara Kostovcikova; Pavel Drastich; Jana Hercogova; Michaela Novakova; Martin Vasatko; Milan Lukas; Helena Tlaskalova-Hogenova; Zuzana Jiraskova Zakostelska Journal: Cells Date: 2021-11-16 Impact factor: 6.600
Authors: Rebecka Ventin-Holmberg; Schahzad Saqib; Katri Korpela; Anne Nikkonen; Ville Peltola; Anne Salonen; Willem M de Vos; Kaija-Leena Kolho Journal: J Fungi (Basel) Date: 2022-03-22
Authors: Jan Marsal; Manuel Barreiro-de Acosta; Irina Blumenstein; Maria Cappello; Thomas Bazin; Shaji Sebastian Journal: Front Med (Lausanne) Date: 2022-06-15
Authors: Maya Olaisen; Mathias L Richard; Vidar Beisvåg; Atle van Beelen Granlund; Elin S Røyset; Olivier Rué; Tom Christian Martinsen; Arne Kristian Sandvik; Harry Sokol; Reidar Fossmark Journal: Front Med (Lausanne) Date: 2022-09-27